Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RPG Life SciencesNSE:RPGLIFE -0.97%88 EV-to-EBIT is 24.70 as of Aug. 28, 2026, which is 44% above its 10-year median of 17.17. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 88/100 and a GF Value™ of ₹2,485.99 (Fairly Valued). The stock has 2 warning signs investors should review. Among 691 Drug Manufacturers companies, RPG Life Sciences ranks worse than 67.87% on this metric.
RPG Life Sciences (NSE:RPGLIFE) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
RPG Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was ₹37,916 Mil.
RPG Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,616 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPG Life Sciences EV-to-EBIT Related Terms
RPG Life Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's EV-to-EBIT falls into.
RPG Life Sciences's current Enterprise Value is ₹39,922 Mil.
RPG Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,616 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPG Life Sciences (NSE:RPGLIFE) has a EV-to-EBIT of 24.70 as of Aug. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on RPG Life Sciences and its competitors. This is 44% above median its historical median of 17.17. Over the past decade, RPG Life Sciences' EV-to-EBIT has ranged from 7.24 to 65.87. According to the industry distribution chart, RPG Life Sciences ranks #469 out of 691 companies in the Drug Manufacturers industry, placing it in the top 67.9%.
Is RPG Life Sciences' EV-to-EBIT too high?
RPG Life Sciences' current EV-to-EBIT of 24.70 is 44% above median its 10-year median of 17.17. Over the past 10 years, this metric has ranged from a low of 7.24 to a high of 65.87. The Drug Manufacturers industry median EV-to-EBIT is 15.71. RPG Life Sciences' value of 24.70 is 57.2% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #469 out of 691 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, RPG Life Sciences has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #469 out of 691 companies for EV-to-EBIT. This places RPG Life Sciences in the lower half of its industry. The industry median EV-to-EBIT is 15.71. RPG Life Sciences' value of 24.70 is 57.2% above this benchmark. Historically, RPG Life Sciences' own EV-to-EBIT has ranged from 7.24 to 65.87 over the past decade. While the company's 10-year median is 17.17 vs. the industry median of 15.71, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.71, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current EV-to-EBIT of 24.70 is 57.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current EV-to-EBIT is 24.70, which is 44% above median its own 10-year median of 17.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,485.99, compared to a current price of ₹2,567.60 — trading 3.3% above its estimated fair value. The current EV-to-EBIT is 24.70, which is 44% above median its 10-year median of 17.17 and 57.2% above the Drug Manufacturers industry median of 15.71. RPG Life Sciences' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current EV-to-EBIT is 24.70 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,567.60 is trading 3.3% above its estimated GF Value™ of ₹2,485.99.
GuruFocus considers RPG Life Sciences to be Fairly Valued.
Key valuation signals for NSE:RPGLIFE:
EV-to-EBIT: 24.70 (44% above median its 10-year median of 17.17)
GF Value™: ₹2,485.99 vs. price of ₹2,567.60 (3.3% above fair value)
Industry Position: 57.2% above the Drug Manufacturers median (#469 of 691)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
88GF Score
Get the complete analysis for NSE:RPGLIFE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
